REFERENCES
1. Barrett-Connor E., Orchard T. Diabetes and heart disease. In: National Diabetes Data Group. Diabetes data compiled 1984. Washington: US Department of Health and Human Services, 1985. XVI-XVI-41.
2. Stamler J., Vaccaro O., Neaton J.D., Westworth D. Diabetes and other risk factors and the 12-year cardiovascular mortality for men screened for the Multiple Risk Factor Intervention Trial. Diabetes Care. 1993; 16: 434–44.
3. Zuanetti G., Latini R., Maggioni A.P., et al. Infl uence of diabetes on mortality in acute myocardial infarction: data from the GISSI-2 study. J Am Coll Cardiol. 1993; 22: 1788–94.
4. Keech A.C., Colquhoun D., Best J., et al. Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial. Diabetes Care. 2003; 26: 2713–21.
5. Butrova S.A. Obesity. Edited by I.I. Dedov, G.A. Melnichenko. Moscow, 2004: 44 p. (in Russian)
6. Zilov A.V. Obesity. Edited by I.I. Dedov, G.A. Melnichenko. Moscow, 2004: 124-54. (in Russian)
7. Ametov A.S., Tertychnaya E.A. Obesity. Edited by A.S. Ametov. Moscow, 2019: 83 p. (in Russian)
8. Baigent C., Blackwell L., Emberson J., et al. Cholesterol Treatment Trialists’ (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet. 2010; 376 (9753): 1670-81.
9. Fruchart J.C., Sacks F., Hermans M.P., et al. The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia. Am J Cardiol. 2008; 102 (suppl): 1K-34K. DOI: https://doi.org/10.1016/j.amjcard.2008.10.002
10. Sampson U.K., Fazio S., Linton M.F. Residual cardiovascular risk despite optimal LDL cholesterol reduction with statins: the evidence, etiology, and therapeutic challenges. Curr Atheroscler Rep. 2012; 14: 1-10. DOI: https://doi.org/10.1007/s11883-011-0219-7
11. Ridker P.M., Genest J., Boekholdt S.M., et al.; JUPITER Trial Study Group. HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial. Lancet. 2010; 376: 333-9. DOI: https://doi.org/101016/S0140-6736(10)60713-1
12. Kim N.H., Han K.H., Choi J., Lee J., Kim S.G. Use of fenofibrate on cardiovascular outcomes in statin users with metabolic syndrome: propensity matched cohort study. BMJ. 2019; 366: l5125. DOI: https://doi.org/10.1136/bmj.15125
13. Elam M.B., et al. Association of fenofibrate therapy with long-term cardiovascular risk in statin-treated patients with type 2 diabetes. JAMA Cardiol. 2017; 2 (4): 370-80. DOI: https://doi.org/10.1001/jamacardio.2016.4828
14. Elam M., Lovato L., Ginsberg H. The ACCORD-Lipid study: implications for treatment of dyslipidemia in type 2 diabetes mellitus. Clin Lipidol. 2011; 6 (1): 9-20.
15. Schoonjans K., Peinado-Onsurbe J., Lefebvre A.M., et al. PPA-Ralpha and PPARgamma activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene. EMBO J. 1996; 15: 5336-48. DOI: https://doi.org/10.1002/j.1460-2075.1996.tb00918.x
16. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005; 366 (9500): 1849-61. DOI: https://doi.org/10.1016/S0140-6736(05)67667-2
17. Instructions for the medicinal use of the drug Suprozafen from 12/04/2020.
18. Jenkins A.J., Rowley K.G., Lyons T.J., Best J.D., Hill M.A., Klein R.L. Lipoproteins and diabetic microvascular complications. Curr Pharm Des. 2004; 10: 3395-418.